Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

Bullish option flow detected in Amgen (AMGN) with 8,403 calls trading, 2x expected, and implied vol increasing over 3 points to 49.64%. Jan-25 ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

A native of De Pere, Wisconsin, Kinziger is considered a four-star recruit by 247Sports, On3 and ESPN. 247Sports ranks the ...

Adial's PK study satisfied an FDA requirement for the AD04 Phase 3 trial. Study confirmed AD04 can be taken with or without ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Supreme Court on Thursday dismissed a plea seeking a direction to mandate doctors to inform patients all kinds of ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...